Trial Profile
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453, After Multiple Topical Applications in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Sep 2014
Price :
$35
*
At a glance
- Drugs LFX 453 (Primary) ; Imiquimod
- Indications Skin disorders
- Focus Adverse reactions; First in man
- Sponsors Novartis
- 28 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Mar 2014 New trial record